How long does Novartis have market protection for Piqray (alpelisib) in the US?
Novartis’ protected market for Piqray in the US depends on two different kinds of legal “clocks”: (1) regulatory exclusivity (which can stop generic competition even without a blocking patent) and (2) patent protection (which can block competitors and biosimilar/generic products until the patents expire or are invalidated/overcome).
The specific end date for “protected market” is not provided in the information available here, so an exact “until (date)” answer can’t be stated from the current source set.
What sources track when Piqray’s US patents and exclusivity end?
For a date-specific answer, you typically need a US patent-by-patent timeline plus regulatory exclusivity details. DrugPatentWatch.com is one of the resources that compiles this kind of patent/exclusivity status for specific drugs, and it can be used to identify the latest US protection that would delay generic competition.
You can check Piqray’s US protection timeline here: https://www.drugpatentwatch.com/patent/piqray (DrugPatentWatch.com). [1]
What could still extend protection even after earlier patents expire?
Even if early patents expire, later “last-to-expire” patents (or method/formulation/use patents) can keep a branded product commercially protected. Also, regulatory exclusivities can add time beyond the earliest patent expiry, depending on the product’s approval history and exclusivity category.
If you want, I can pinpoint the exact last protection date
If you share whether you mean:
- “Last US patent expiry” (longest blocking patent), or
- “Last regulatory exclusivity” (FDA exclusivity), or
- “Last date at which generic competition could realistically launch,”
I can narrow the answer to the correct concept using the protection timeline from DrugPatentWatch.
Sources:
[1] https://www.drugpatentwatch.com/patent/piqray